What is Oncopole?
Oncopole is a Quebec-based hub dedicated to accelerating the fight against cancer through research, development, and strategic investment. Positioned at the forefront of oncology innovation, the organization aims to foster collaboration and drive progress in therapeutic breakthroughs and diagnostic advancements. Its focus on a multi-faceted approach, encompassing research, development, and investment, highlights its commitment to a comprehensive strategy for combating cancer.
How much funding has Oncopole raised?
Oncopole has raised a total of $5.5M across 1 funding round:
Other Financing Round
$5.5M
Other Financing Round (2023): $5.5M with participation from Merck & Co, Pfizer, and GSK
Key Investors in Oncopole
Merck & Co
Merck & Co. is a global healthcare company with a long history of delivering innovative solutions in medicines, biologics, vaccines, and animal health.
Pfizer
Pfizer is a biopharmaceutical company focused on researching, developing, and manufacturing medicines and vaccines across various therapeutic areas, including oncology.
GSK
GSK plc is a British multinational pharmaceutical and biotechnology company with a strong research and development focus on oncology, immunology, and infectious diseases.
What's next for Oncopole?
The recent major strategic investment signals a new phase of accelerated growth and development for Oncopole. This influx of capital is expected to fuel further research initiatives, expand its R&D capabilities, and potentially broaden its investment portfolio within the oncology sector. The company is poised to leverage this strategic backing to solidify its position as a key player in the global fight against cancer, driving innovation and fostering a robust ecosystem for therapeutic advancements.
See full Oncopole company page
